Effectiveness and Safety of Immune Checkpoint Inhibitors in Older Cancer Patients
Authors:
- Damir VucinicDVDamir Vucinic
- Iva SkocilicISIva Skocilic
- Marin GolcicMarin Golcic
- Renata Dobrila-DintinjanaRDRenata Dobrila-Dintinjana
- Maja KolakMaja Kolak
- Ivona JerkovicIJIvona Jerkovic
- Eleonora Cini TesarETEleonora Cini Tesar
- Ani Mihaljevic FerariAFAni Mihaljevic Ferari
- Arnela RedjovicARArnela Redjovic
- Jasna MarusicJMJasna Marusic
- Doris KolovratDKDoris Kolovrat
- Ivana MikolasevicIMIvana Mikolasevic
Open Access
- 1 March 2024
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (3) , 278
Abstract
Background: The development of immunotherapy checkpoint inhibitors (ICIs) has revolutionized cancer care. However, old patients are underrepresented in most clinical trials, although they represent a significant proportion of real-world patients. We aimed to evaluate the effectiveness and safety of ICIs in patients older than the age of 70. Methods: We performed a retrospective chart review of 145 patients aged 70 or older treated with ICIs for metastatic or unresectable cancer. Results: Median progression-free survival (PFS) was 10.4 months (95% CI 8.6–13.7), with no differences between octogenarians and septuagenarians (p = 0.41). Female gender (p = 0.04) and first-line treatment setting (p < 0.0001) were associated with a longer median PFS. Median overall survival (OS) was 20.7 months (95% CI 13.5–35.0 months), with no difference based on performance status, cancer site, gender, or between septuagenarians and octogenarians (all p > 0.005). Patients treated with ICIs in the first-line setting reported longer OS compared to treatment in the second-line setting (p < 0.001). Discontinuation of ICIs due to adverse effects was associated with both shorter PFS (p = 0.0005) and OS (p < 0.0001). Conclusion: The effectiveness of ICIs in older cancer patients primarily depends on the line of treatment and treatment discontinuation. Octogenarians experienced similar treatment responses, PFS, OS, and adverse effects compared to septuagenarians.Keywords
This publication has 24 references indexed in Scilit:
- The use of immunotherapy in older patients with advanced non-small cell lung cancerCancer Treatment Reviews, 2022
- Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With CancerJAMA Oncology, 2021
- Immunotherapy in older patients with cancerBiomedical Journal, 2021
- A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients – the ELDERS studyESMO Open, 2021
- Estimated global cancer incidence in the oldest adults in 2018 and projections to 2050International Journal of Cancer, 2020
- Gender Differences and Outcomes in Melanoma PatientsOncology and Therapy, 2020
- Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical TrialsJAMA Oncology, 2019
- Immunotherapy in Older Adults with CancerCurrent Oncology Reports, 2019
- Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced CancersJAMA Oncology, 2019
- Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysisCancer Treatment Reviews, 2016